Description
The 1F11/TSLPR monoclonal antibody specifically binds to Thymic Stromal Lymphopoietin Receptor (TSLPR). TSLPR is a member of the hematopoietin receptor superfamily and is also known as Cytokine Receptor-like Factor 2 (CRL2, CRLF2Y, CRLF2). The functional TSLPR complex consists of two subunits, TSLPR and the alpha subunit of the Interleukin-7 Receptor (IL-7Rα). Analysis of the TSLPR reveals sequence similarity with the common cytokine receptor gamma chain (γc; CD132). Functional TSLPRs are expressed by epithelial cells and a variety of hematopoietic cell types, including thymocytes, T cells, B cells, natural killer T cells, monocytes, macrophages, basophils, and dendritic cells (DC). Recent studies indicate that TSLP can activate multiple STAT (Signal Transducer and Activator of Transcription) signaling proteins. TSLP enhances the maturation and viability of DC. It strongly induces DC expression of the CD40 and CD80 costimulatory molecules and chemokines, e.g., TARC (Thymus and activation-regulated chemokine; CCL17) that can attract Th2 effector cells. TSLP supports B cell development. TSLP costimulates the proliferation of naïve T cells in the presence of mature DC. TSLP is also able to increase the sensitivity of T cell receptor-activated CD4+ T cells to low doses of IL-2. In the presence of TSLP, the acute myeloid leukemia-derived cell line, MUTZ-3, shows induced growth and reduced apoptosis. CRLF2 deregulated gene expression is thought to be involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. The 1F11/TSLPR antibody is reportedly a neutralizing antibody.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. BD Horizon Brilliant Violet 510 is covered by one or more of the following US patents: 8,575,303; 8,354,239.
